Has Gregory Levitin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,109 in general payments to Gregory Levitin, MD across 224 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregory Levitin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregory Levitin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregory Levitin, MD

Otolaryngology · New York, NYNPI 1801981931

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,350 of the $12,109 with a category attached, or 85.5%. 15 manufacturers reported payments, led by Neurent Medical Limited at 44.0% of the total. 2025 is the largest year on record at $3,963, 4.5 times the $885 reported in 2019. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,109in general payments, 2019–2025

Across 224 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurent Medical Limited$5K
Stryker$3K
Aerin Medical Inc.$2K
Spirair, Inc.$480
Optinose US, Inc.$298
Sanofi$288
plus $1K from 9 others

$35,740in research payments, 2019–2025

Across 4 payments — averaging $8935.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Aerin Medical Inc.$36K

What the payments were for

Consulting fees$7506%
Travel & lodging$1,0098%
Food & beverage$10,35085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurent Medical Limited	86	$5,331
Stryker	64	$2,722
Aerin Medical Inc.	16	$1,887
Spirair, Inc.	2	$480
Optinose US, Inc.	11	$298
Sanofi	12	$288
GSK	12	$258
Intersect ENT, Inc.	4	$213
Regeneron Healthcare Solutions, Inc.	5	$195
Acclarent, Inc	3	$145
AstraZeneca	2	$121
Novartis	4	$97
Medtronic	1	$28
Arrinex, Inc.	1	$25
Amgen	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NEUROMARK Device$1,857
NEUROMARK Radiofrequency Console$1,351
VIVAER STYLUS$1,335
RHINAER STYLUS$1,335
SeptAlign$858
TURBALIGN$858
NEUROMARK Radiofrequency Generator$661
XPRESS ENT DILATION SYSTEM$258
ENTELLUS - XPRESS ENT DILATION SYSTEM$247
LATERA$168
NEUROMARK System$156
DUPIXENT$120
Xhance$100

How this compares

$12,109 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$295,734

Medicare patients

101

Services billed

568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	106	$2,982
Fluticasone Propionate	11	$102
Azithromycin	32	$98
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	13	$62
Prednisone	33	$33
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	15	$31

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New York

Roheen RaithathaNew York$830K
Dennis KrausNew York$159K
Anthony DelsignoreNew York$89K
Satish GovindarajNew York$39K
Lawrence LustigNew York$33K
Justin GolubNew York$30K
Brett MilesNew York$30K
David HiltzikNew York$25K
Milan AminNew York$23K
Ashutosh KackerNew York$20K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →